Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Safety and Efficacy Study of Natural Killer and Natural Killer T Cell Immunotherapy in Patients With Non Small Cell Lung Cancer

NCT03198923 is registered in ClinicalTrials.gov with Wenxiang Wang as lead sponsor.

NCT NCT03198923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03198923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Safety and Efficacy Study of Natural Killer and Natural Killer T Cell Immunotherapy in Patients With Non Small Cell Lung Cancer
Lead sponsor
Wenxiang Wang
Phase
Phase 1
Overall status
Unknown status
Start date
September 13, 2017
Completion date
December 31, 2020
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer